Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 9/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213331 | 0.85 | MEN1 (0.41) | SIGMAR1HTR1ADRD2SLC6A4PSMB8 | |
| SCHEMBL6216523 | 0.81 | MAOB (0.48) | DRD2PSMB8PSMB5DRD3 | |
| SCHEMBL6215084 | 0.80 | SIGMAR1 (0.55) | SIGMAR1HTR1ADRD2SLC6A4DRD3 | |
| SCHEMBL5564087 | 0.78 | DRD2 (0.50) | SIGMAR1HTR1ADRD2SLC6A4DRD3 | |
| SCHEMBL6216772 | 0.78 | PSMB8 (0.39) | SIGMAR1HTR1ADRD2SLC6A4PSMB8 | |
| SCHEMBL6214069 | 0.76 | DRD2 (0.42) | SIGMAR1HTR1ADRD2SLC6A4DRD3 | |
| SCHEMBL5569217 | 0.76 | SLC6A4 (0.48) | SIGMAR1HTR1ADRD2SLC6A4DRD3 | |
| SCHEMBL7827907 | 0.76 | KCNA3 (0.46) | DRD2DRD3 | |
| SCHEMBL6212612 | 0.70 | DRD2 (0.41) | SIGMAR1HTR1ADRD2PSMB8PSMB5 | |
| SCHEMBL6214207 | 0.66 | HTR1A (0.48) | SIGMAR1HTR1ADRD2SLC6A4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1122254-B1 | 4-Sulfonamide piperidine derivatives, method for their preparation and phamaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-6323217-B2 | CARDIOVASCULAR DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-25 | — | — | US | disclosed |
| EP-1122254-A2 | 4-Sulfonamide piperidine derivatives, method for their preparation and phamaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | KDR, GLS, FLT1 | SIGMAR1 80/4885HTR1A 94/4885DRD2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.